Compare KHC & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KHC | NTRA |
|---|---|---|
| Founded | 1869 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4B | 32.9B |
| IPO Year | 2015 | 2015 |
| Metric | KHC | NTRA |
|---|---|---|
| Price | $24.40 | $212.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 14 |
| Target Price | $26.13 | ★ $253.79 |
| AVG Volume (30 Days) | ★ 15.5M | 940.2K |
| Earning Date | 05-14-2026 | 04-06-2026 |
| Dividend Yield | ★ 6.67% | N/A |
| EPS Growth | N/A | ★ 59.52 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,942,000,000.00 | $210,939,000.00 |
| Revenue This Year | N/A | $34.18 |
| Revenue Next Year | $0.41 | $16.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.99 | $125.38 |
| 52 Week High | $33.35 | $256.36 |
| Indicator | KHC | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 45.24 |
| Support Level | $23.44 | $204.04 |
| Resistance Level | $24.25 | $220.65 |
| Average True Range (ATR) | 0.71 | 9.15 |
| MACD | -0.02 | 0.41 |
| Stochastic Oscillator | 38.92 | 49.48 |
In July 2015, Kraft merged with Heinz to create one of North America's largest food and beverage manufacturers. Beyond its namesake brands, its portfolio includes Oscar Mayer, Velveeta, and Philadelphia. While the retail channel drives around 85% of its total sales, the firm also maintains a growing foodservice presence. Outside North America, Kraft Heinz's global reach encompasses a distribution network in Europe and emerging markets, which accounts for around 25% of its consolidated sales base. The company's products are sold in more than 190 countries and territories.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.